Loading
Life sciences · Journal article
Journal of Dental Research · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Traditional photodynamic therapy (PDT), chemodynamic therapy (CDT), and photothermal therapy (PTT) for oral squamous cell carcinoma (OSCC) face inherent limitations, including oxygen dependence, insufficient endogenous H 2 O 2, and nonspecific thermal diffusion. To address these challenges, we developed a near infrared (NIR) responsive theranostic platform based on Au@RCDs@GOx. This system leverages a single NIR wavelength to trigger plasmon enhanced cascade therapy integrating PTT ablation, glucose oxidase (GOx) generated H 2 O 2, photo amplified CDT, and starvation therapy. Importantly, photoexcited electrons are injected into the flavin adenine dinucleotide (FAD) cofactor of GOx via the red emitting carbon dots (RCD) shell, enabling sustained reactive oxygen species (ROS) generation even under glucose deprived conditions through direct 1-electron reduction of O 2 to superoxide anions (·O 2 − ). Meanwhile, Au@RCDs@GOx exhibit excellent surface-enhanced Raman scattering (SERS) activity, providing real-time feedback on oxidative stress within the tumor microenvironment. In an OSCC xenograft model, intratumoral administration of this platform at an ultralow dose (0.12 mg kg −1 ) achieved 95.7% tumor suppression with excellent biosafety. This work establishes photoenzymatic catalysis as an adaptive and synergistic paradigm for cancer therapy with integrated SERS monitoring.